Cybin Announces Transfer to Nasdaq with New Ticker Symbol Reflecting Mental Health Mission

Cybin Inc., a clinical-stage pharmaceutical company developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The company expects its common shares to cease trading on NYSE American at market close on Jan. 4, 2026, and to begin trading on Nasdaq at market open on Jan. 5, 2026, at which time the ticker symbol will change from "CYBN" to "HELP." Cybin will remain listed on Cboe Canada and will also trade under the "HELP" ticker on that exchange beginning Jan. 5, 2026. The ticker change to HELP directly reflects the company's mission as a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare.

The transfer to Nasdaq, a premier exchange for growth companies, particularly in the biotechnology and pharmaceutical sectors, provides Cybin with enhanced visibility among institutional investors and analysts who follow the mental health treatment space. The timing of this move coincides with the company's progression of its key clinical assets through advanced trial phases, positioning Cybin at a critical juncture in its development timeline. Cybin is developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising class-leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients.

The company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The company also maintains a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The move to Nasdaq represents a strategic step for the company as it advances its clinical programs. Investors can access the latest news and updates relating to Cybin in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the listing transfer is available at https://ibn.fm/pcrpA.